莫沙必利联合马来酸曲美布汀治疗功能性消化不良的效果观察

Effects of mosapride combined with trimebutin maleate on patients with functional dyspepsia

目的探讨莫沙必利联合马来酸曲美布汀治疗功能性消化不良(FD)的临床效果。方法回顾性分析2017年2月至2019年3月于山西大同煤矿集团总医院接受治疗的81例FD患者的临床资料,依据治疗方案将其分为观察组及对照组,其中41例采用莫沙必利联合马来酸曲美布汀治疗的患者作为观察组,40例采用消化酶联合莫沙必利治疗的患者作为对照组。比较两组治疗前后血清神经肽S受体1(NPSR-1)、降钙素基因相关肽(CGRP)、胃动素(MTL)水平及胃肠排空率。观察两组患者给药期间的不良反应发生情况。结果治疗后,两组胃肠排空率均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组NPSR-1、MTL水平升高,CGRP水平降低,且观察组NPSR-1、MTL水平高于对照组,CGRP水平低于对照组,差异有统计学意义(P<0.05)。给药期间,对照组不良反应发生率为2.50%(1/40),观察组不良反应发生率为7.32%(3/41),两组比较差异未见统计学意义(χ^2=0.238,P=0.317)。结论采用莫沙必利联合马来酸曲美布汀治疗FD安全有效,能显著增强患者的胃肠动力。

Objective To investigate the effects of mosapride combined with trimebutin maleate on functional dyspepsia(FD)patients.Methods The clinical data of 81 FD patients treated in Datong Coal Mine Group General Hospital from February 2017 to March 2019 were retrospectively analyzed.According to the treatment protocols,they were divided into the observation group and control group.Patients treated with mosabil+trimebutin maleate were selected as observation group(n=41),and patients treated with digestive enzyme+mosabil were selected as the control group(n=40).The levels of serum neuropeptide S receptor 1(NPSR-1),calcitonin gene-related peptide(CGRP),motilin(MTL)and gastrointestinal emptying rate of the two groups before and after treatment were compared.And incidence of adverse reactions during administration were compared between the two groups.Results After treatment,the gastrointestinal emptying rate of the two groups was higher than that before treatment,and gastrointestinal emptying rate of the observation group was higher than that of the control group(P<0.05).After treatment,the levels of NPSR-1 and MTL in the two groups increased,while the levels of CGRP decreased,and the levels of NPSR-1 and MTL in the observation group were higher than those in the control group,while the levels of CGRP in the observation group were lower than those in the control group(P<0.05).During administration,the incidence of adverse reactions was 2.50%(1/40)in the control group,and 7.32%(3/41)in the observation group;there was no significant difference in the incidence between the two groups(χ^2=0.238,P=0.317).Conclusions The combination of mosabil and trimebutin maleate is safe and effective in treating FD,and can significantly enhance the gastrointestinal motivity of the patients.